Veterinary Vaccines Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Animal (Livestock, Companion Animals), By Type (Live, Attenuated Vaccine, Inactivated/Killed Vaccine, Toxoid (Inactive Toxin) Vaccine, Subunit/Conjugate Vaccine), By Route Of Administration (Oral, Parental, Others), And By Geography - Forecasts From 2022 To 2027

  • Published : Nov 2022
  • Report Code : KSI061611783
  • Pages : 138

The veterinary vaccine market is projected to grow at a CAGR of 5.85% during the forecast period to reach US$10.596 billion by 2027, from US$7.119 billion in 2020.

Veterinary vaccines are crucial for animal health, welfare, food production, and public health among others. They are an affordable way to stop animal sickness, improve the effectiveness of food production, and lessen or stop the spread of zoonotic and foodborne pathogens to humans. Animal vaccines that are both safe and efficacious are crucial to modern society. Vaccines prevent epizootics in food-producing animals, facilitating the production of animal protein to feed the massive population. Further, the increasing adoption of animal companions coupled with the growing incidence of animal diseases fuels the growth of the market. Growth in the livestock population and increasing initiatives by the government along with the involvement of animal associations widen the market growth opportunities. Moreover, there is also a growing awareness of animal health with works as the key driver for the growth in the market. Governments are also taking initiatives to launch and develop veterinary vaccines for animal well-being and good health. For instance, the Department of Animal Husbandry and Dairying of India has a Livestock Health and Disease control scheme under which the department aims to improve the animal health sector by way of implementation of prophylactic vaccination programs against various diseases of livestock and poultry. The program's goals are to conduct a critical animal disease control program to vaccinate all sheep and goats in order to eradicate PPR by 2030 and to vaccinate all pigs in order to control Classical Swine Fever (CSF). These factors are expected to propel the market growth of the veterinary vaccines market during the anticipated period.

The Veterinary vaccines market will grow due to the rising cases of zoonotic diseases in developed and developing countries.

Zoonotic diseases or zoonoses are diseases spread by animals to people. Animals carry harmful germs that can spread diseases, such as harmful germs like viruses, bacteria, parasites, and fungi. Zoonotic diseases can have clinical effects that are minor to severe and occasionally fatal. Zoonotic diseases are pervasive across the world. According to the Centers for Disease Control (CDC), more than six out of ten infectious diseases that affect humans now can spread through animals, and three out of every four new or developing infectious diseases that affect humans will originate from animals. Furthermore, in the past few years, several new infectious human diseases causing viruses, such as Ebola virus, west Nile virus, and Hantavirus infections have emerged from animal reservoirs. The outbreaks have become more frequent of such viruses, which is creating a dire necessity to protect against such outbreaks.

Furthermore, the government initiatives to tackle these virus-spread issues among animals have also supported the growth of the veterinary vaccines market during the forecast period. For instance, in June 2022, the Ministry of Agriculture and Farmers Welfare of India announced the launch of animal vaccines and kits which were developed by the ICAR-NRC on equines. These Ancovax Vaccines on Equines are inactivated SARS-CoV-2 Delta vaccines for animals. The vaccine includes Alhydrogel as an adjuvant and inactivated SARS-CoV-2 (Delta) antigen. Further, the ministry announced that the vaccine is safe for dogs, lions, leopards, mice, and rabbits.  Hence, the growth of incidences of zoonotic diseases is expected to boost the veterinary vaccine market in the forecast period.

The Veterinary vaccines market is expected to be dominated by the North American region, which is expected to hold a significant share of the veterinary vaccine market.

The high incidence of livestock and zoonotic illnesses causing widespread animal fatalities can be blamed for this substantial share. Additionally, the prevalence of established pharmaceutical companies, who continually work to expand their geographic reach and promote the widespread marketing of their vaccines, is anticipated to spur market expansion. Additionally, the rising pet population in the United States and the rising frequency of canine diseases, which are raising the use of vaccination against them, are some of the major drivers of the regional market's rise.

Key Development

  • In July 2022, Zoetis expanded its poultry vaccine portfolio by introducing Poulvac® Procerta®HVT-IBD-ND, a recombinant vector vaccine that provides early protection against infectious bursal and Newcastle disease viruses with one dose. The vaccine aids to boost the immunogenicity that sets it apart from other vaccines in the same category claims the company.
  • Merck Animal Health announced the launch of Nobivac®Intra-trac®Oral BbPi, the first and only oral Bordetella bronchiseptics-canine parainfluenza virus vaccine and revolutionary Immuno-Mist-RTM applicator that delivers broad protection and enhances ease of use and pet comfort.

COVID-19 Impact on the Veterinary Vaccines Market

The COVID-19 pandemic resiliently impacted the veterinary vaccine market. The robust outbreak of the virus and its exponential spread resulted in the implementation of a nationwide lockdown. Stuck at home, increase anxiety and consciousness among people led to increasing adoption of pets. According to the Prospectus of Tanmiah Food Company published in 2021, the Kingdom of Saudi Arabia reportedly controlled the largest animal vaccinations market in the GCC in 2020 with a total requirement of 316 million doses for the same.

Veterinary Vaccines Market Scope:


Report Metric Details
 Market Size Value in 2020  US$7.119 billion
 Market Size Value in 2027  US$10.596 billion
 Growth Rate  CAGR of 5.85% from 2020 to 2027
 Base Year  2020
 Forecast Period  2022–2027
 Forecast Unit (Value)  USD Billion
 Segments Covered  Animal, Type, Route of Administration, And Geography
 Regions Covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies Covered Elanco, Zoetis, Ceva, Merck Animal Health, Phibro Animal Health, Virbac, Hester, Hipra, Boehringer Ingelheim International GmbH
 Customization Scope  Free report customization with purchase


Market Segments

  • By Animal
    • Livestock
    • Companion Animals
  • By Type
    • Live, Attenuated Vaccines
    • Inactivated/Killed Vaccines
    • Toxoid (Inactive Toxin) Vaccines
    • Subunit/Conjugate Vaccines
  • By Route Of Administration
    • Oral
    • Parental
    • Others
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • Germany
      • France
      • United Kingdom
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • Israel
      • Others
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • Others

Frequently Asked Questions (FAQs)

The global veterinary vaccine market is projected to grow at a CAGR of 5.85% during the forecast period.
The veterinary vaccine market is projected to reach a market size of US$10.596 billion by 2027.
Veterinary Vaccines Market was valued at US$7.119 billion in 2020.
The North American region is expected to hold a significant share of the veterinary vaccine market.
The increasing adoption of animal companions coupled with the growing incidence of animal diseases fuels the veterinary vaccine market growth.


1.1. Market Overview

1.2. COVID-19 Scenario

1.3. Market Definition

1.4. Market Segmentation



2.1. Research Data

2.2. Assumptions



3.1. Research Highlights



4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis



5.1. Introduction

5.2. Livestock 

5.3. Companion Animals



6.1. Introduction

6.2. Live, Attenuated Vaccines

6.3. Inactivated/Killed Vaccines

6.4. Toxoid (Inactive Toxin) Vaccines

6.5. Subunit/Conjugate Vaccines



7.1. Introduction

7.2. Oral

7.3. Parental

7.4. Others



8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. Germany

8.4.2. France

8.4.3. United Kingdom

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. Israel

8.5.3. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. Japan

8.6.3. India 

8.6.4. South Korea

8.6.5. Others



9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrative

9.3. Mergers, Acquisition, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix



10.1. Elanco

10.2. Zoetis

10.3. Ceva

10.4. Merck Animal Health

10.5. Phibro Animal Health

10.6. Virbac

10.7. Hester

10.8. Hipra

10.9. Boehringer Ingelheim International GmbH




Merck Animal Health

Phibro Animal Health




Boehringer Ingelheim International GmbH